Question 1

What is LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN used for?

Accepted Answer

LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN (brand name PLUVICTO) is a Other indicated for and are considered appropriate to delay taxane-based chemotherapy, and are considered appropriate to delay taxane-based chemotherapy, or have received prior taxane-based chemotherapy. ( 1 ).

Question 2

How does LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN work?

Accepted Answer

LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN works through the following mechanism: 12.1 Mechanism of Action Lutetium Lu 177 vipivotide tetraxetan is a radioligand therapeutic agent. The active moiety of lutetium Lu 177 vipivotide tetraxetan is the radionuclide lutetium-177 which is linked to a moiety that binds to PSMA, a transmembrane protein that is expressed in prostate cancer, including mCRPC. Upon binding of lutetium Lu 177 vipivotide tetraxetan to PSMA-expressing cells, the beta-minus emission from lutetium-177 delivers radiation to PSMA-expressing cells, as well as to surrounding cells, and induces DNA damage which can lead to cell death..

Question 3

What are the most common side effects of LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN?

Accepted Answer

Reported side effects vary by individual. The side-effects section on this page lists the events most frequently reported to FDA FAERS for LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN. FAERS is voluntary reporting, so it reflects what was reported, not absolute incidence.

Question 4

Is LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN the same as PLUVICTO?

Accepted Answer

PLUVICTO is a brand name for LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN. They share the same active ingredient and FDA-approved indications. Biosimilars and authorised generics may differ in inactive ingredients such as buffers or preservatives.

LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN

Mechanism of Action

Indications

FDA Warnings

Known Side Effects

Community Discussions

Primary sources

Compare With

Formulations